Revenue Breakdown
Composition ()
No data
Revenue Streams
Regeneron Pharmaceuticals Inc (REGN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sanofi, accounting for 43.1% of total sales, equivalent to $1.62B. Other significant revenue streams include EYLEA and EYLEA HD. Understanding this composition is critical for investors evaluating how REGN navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Regeneron Pharmaceuticals Inc maintains a gross margin of 86.11%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 29.56%, while the net margin is 40.07%. These profitability ratios, combined with a Return on Equity (ROE) of 15.34%, provide a clear picture of how effectively REGN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, REGN competes directly with industry leaders such as GSK and SNY. With a market capitalization of $79.05B, it holds a significant position in the sector. When comparing efficiency, REGN's gross margin of 86.11% stands against GSK's 73.86% and SNY's 68.80%. Such benchmarking helps identify whether Regeneron Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
